NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free ARCT Stock Alerts $31.82 -10.78 (-25.31%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$29.73▼$42.4250-Day Range$25.57▼$44.3952-Week Range$17.52▼$45.00Volume2.31 million shsAverage Volume485,121 shsMarket Capitalization$856.91 millionP/E RatioN/ADividend YieldN/APrice Target$64.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside103.8% Upside$64.86 Price TargetShort InterestHealthy16.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 11 Articles This WeekInsider TradingSelling Shares$1.96 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.39) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.76 out of 5 starsMedical Sector341st out of 905 stocksPharmaceutical Preparations Industry155th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.81% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 16.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 2.7 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search Interest10 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,955,824.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($4.39) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressTime is Running Out - June 25th Deadline Approaching!If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesJune 5 at 5:42 AM | insidertrades.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 26,000 SharesJune 8 at 3:51 AM | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by BrokeragesJune 6 at 4:44 AM | americanbankingnews.comPad Chivukula Sells 26,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) StockMay 28, 2024 | msn.comArcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously OptimisticMay 28, 2024 | marketwatch.comArcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis TreatmentMay 28, 2024 | businesswire.comArcturus Therapeutics Announces Positive Development for Cystic Fibrosis ProgramMay 27, 2024 | msn.comCSL and Arcturus Announce Breakthrough COVID-19 Vaccine Study ResultsMay 20, 2024 | prnewswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 20, 2024 | businesswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics Amidst Promising Gene Therapy AdvancesMay 15, 2024 | businesswire.comArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesMay 12, 2024 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards GrowthMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical AdvancementsMay 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights:May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | investorplace.comARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comArcturus Therapeutics: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressApril 29, 2024 | finance.yahoo.comArcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five yearsApril 25, 2024 | businesswire.comArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024April 23, 2024 | seekingalpha.comArcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic FibrosisApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)See More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/08/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$64.86 High Stock Price Target$90.00 Low Stock Price Target$45.00 Potential Upside/Downside+103.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-81.59% Pretax Margin-82.40% Return on Equity-37.61% Return on Assets-23.99% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual Sales$169.93 million Price / Sales5.04 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book3.05Miscellaneous Outstanding Shares26,930,000Free Float23,215,000Market Cap$856.91 million OptionableOptionable Beta2.76 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MDr. Padmanabh Chivukula Ph.D. (Age 45)Founder, Chief Scientific Officer, COO & Secretary Comp: $787.5kMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerJoseph RobertsControllerMore ExecutivesKey CompetitorsStoke TherapeuticsNASDAQ:STOKNurix TherapeuticsNASDAQ:NRIXLigand PharmaceuticalsNASDAQ:LGNDArcus BiosciencesNYSE:RCUSShattuck LabsNASDAQ:STTKView All CompetitorsInsiders & InstitutionsPad ChivukulaSold 114 sharesTotal: $5,130.00 ($45.00/share)Pad ChivukulaSold 26,000 sharesTotal: $1.04 M ($40.01/share)Boston PartnersBought 17,169 shares on 5/28/2024Ownership: 0.064%Teachers Retirement System of The State of KentuckyBought 15,305 shares on 5/28/2024Ownership: 0.057%Tidal Investments LLCBought 6,877 shares on 5/17/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares. View ARCT analyst ratings or view top-rated stocks. What is Arcturus Therapeutics' stock price target for 2024? 7 brokers have issued 1 year price targets for Arcturus Therapeutics' shares. Their ARCT share price targets range from $45.00 to $90.00. On average, they expect the company's share price to reach $64.86 in the next twelve months. This suggests a possible upside of 103.8% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts. How have ARCT shares performed in 2024? Arcturus Therapeutics' stock was trading at $31.53 at the beginning of 2024. Since then, ARCT shares have increased by 0.9% and is now trading at $31.82. View the best growth stocks for 2024 here. Are investors shorting Arcturus Therapeutics? Arcturus Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 4,130,000 shares, a decrease of 16.1% from the April 30th total of 4,920,000 shares. Based on an average trading volume of 506,100 shares, the short-interest ratio is presently 8.2 days. Currently, 16.8% of the shares of the company are sold short. View Arcturus Therapeutics' Short Interest. When is Arcturus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our ARCT earnings forecast. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its earnings results on Wednesday, May, 8th. The biotechnology company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.17. The biotechnology company earned $38.01 million during the quarter, compared to analysts' expectations of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative trailing twelve-month return on equity of 37.61%. What ETFs hold Arcturus Therapeutics' stock? ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), Subversive Mental Health ETF (SANE), Amplify Treatments, Testing and Advancements ETF (GERM), WisdomTree BioRevolution Fund (WDNA), AXS Green Alpha ETF (NXTE), Jacob Forward ETF (JFWD) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.15%), Sumitomo Mitsui Trust Holdings Inc. (4.74%), Nikko Asset Management Americas Inc. (4.74%), Jacobs Levy Equity Management Inc. (0.36%), Nordea Investment Management AB (0.21%) and Assenagon Asset Management S.A. (0.21%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARCT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredNvidia has Apple and Microsoft within striking rangeA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. W...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.